Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.71 |
| ▸ | RET | P07949 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | AGPAT2 | O15120 | 3/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6506752 | 0.83 | SYK (1.00) | SYKRETKDRMAP3K11RAF1 | |
| SCHEMBL5334372 | 0.73 | KDR (0.59) | SYKRETKDRMAP3K11RAF1 | |
| SCHEMBL25294010 | 0.73 | SYK (0.72) | SYKRETKDRMAP3K11 | |
| SCHEMBL30338423 | 0.73 | SYK (0.72) | SYKRETKDRMAP3K11 | |
| SCHEMBL1059535 | 0.71 | SYK (0.70) | SYKRETKDR | |
| SCHEMBL6495504 | 0.71 | KDM4E (0.54) | KDM4EALDH1A1MAPTHPGDNPSR1 | |
| SCHEMBL14320776 | 0.69 | RET (0.56) | SYKRETKDRRAF1BRAF | |
| SCHEMBL6508688 | 0.68 | MAP4K4 (0.39) | SYKRETKDRKDM4EALDH1A1 | |
| SCHEMBL2479094 | 0.68 | SYK (1.00) | SYK | |
| SCHEMBL2431323 | 0.67 | SYK (0.75) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911443-B2 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-06-28 | — | — | US | claimed |
| EP-1278750-B1 | IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-08-04 | — | — | EP | claimed |
| US-20040054179-A1 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-03-18 | — | — | US | claimed |
| US-6911443-B2 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-06-28 | — | — | US | disclosed |
| EP-1278750-B1 | IMIDAZOPYRIMIDINE DERIVATIVES AND TRIAZOLOPYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-08-04 | — | — | EP | disclosed |
| US-20040054179-A1 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054179-A1 | Imidazopyrimidine derivatives and triazolopyrimidine derivatives | XRCC6, XRN2, HRH2 | SYK 1025/4885RET 1227/4885KDR 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.